HC Wainwright & Co. Reiterates Buy on Gracell Biotechnologies, Maintains $12 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Gracell Biotechnologies (NASDAQ:GRCL) with a Buy and maintains $12 price target.
Gracell Biotech’s Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates
Gracell Biotechnologies Inc (NASDAQ:GRCL) announced the clinical data from its ongoing Phase 1 investigator-initiated trial (IIT) in China evaluating GC012F as…
Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims
HC Wainwright initiated coverage on Gracell Biotechnologies Inc (NASDAQ:GRCL) with a Buy rating and a price target of $6. The China-based company…
HC Wainwright & Co. Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and announces Price Target of $6.
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers
FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Citigroup Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $12
Citigroup analyst Yigal Nochomovitz initiates coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and announces Price Target of $12.
Gracell Biotechnologies: Q2 Earnings Insights
Gracell Biotechnologies (NASDAQ:GRCL) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Recap: Gracell Biotechnologies Q2 Earnings
Gracell Biotechnologies (NASDAQ:GRCL) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.